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Cardiac energy metabolism is complex and has three main
components: 1. Substrate utilisation, 2 Oxydative phosphorilation
and 3. Transfer of high energy phosphates. Substrate utilization
involves the cellular uptake of free fatty acids, glucose and amino
acids, their breakdown by beta-oxidation and glycolysis, and the
entry of Acetyl Coenzyme A into the Krebs cycle. Oxidative
phosphorylation involves the production of energy by the mito-
chondrial respiratory chain and the production of high-energy
phosphates.
Until recent it was not known that it was possible to delimitate
the infarct size through therapeutic interventions. Likely, the
improvement to understand the mechanisms of cellular survivor
occurs in that year, when Murry et al. discovered an intrinsic
mechanism of myocardial protection, which they denominated as
ischemic preconditioning. In that experiment, it was observed that
four cycles of ﬁve minutes of ischemia, with intermittent reperfusion,
before 40 min of ischemia period, resulted in reduction of 75% of the
infarct size. Also, it was demonstrated by these researches that this
protection it was not resulted by collateral overture and that
protective effect of the ischemic preconditioning was abolished in
the presence of prolonged ischemia, with duration of 3 h.
Two phenomenons, the walk-through angina and the warm up
phenomenon could represent a clinical manifestation of precondi-
tioning. The phenomenon of walk-through angina was ﬁrst related in
the end of century XVIII in a patient that developed angina during
the effort, but experimented the paradox disappearing of the pain
with the exercise continuation. The exact molecular mechanisms
involved in ischemic preconditioning are not fully elucidated.
Therefore, due to the high prevalence of risk factors to cardio-
vascular diseases and the high morbidity and mortality associated
with coronary artery disease, there is a needed to understand even
better the cardiac metabolism during ischemia and the strategies to
reduce the consequences of the ischemia, to preserve the viability of
the ischemic myocardium.
doi:10.1016/j.ijcme.2015.05.002
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The diffuse distribution of atherosclerosis in patients with type 2
diabetes mellitus is related in part to the metabolic derangements of
diabetes and in part to the clustering of different risk factors such as
elevated blood pressure, central obesity and altered lipid proﬁle.
In patients with diabetes mellitus and coronary artery disease the
metabolic changes occurring as a consequence of the mismatch
between blood supply and cardiac metabolic requirements are
heightened by the diabetic metabolic changes. The presence of
myocardial insulin resistance has been demonstrated in diabetic
patients with and without coronary artery disease suggesting that
even early stages of altered glycaemic control may affect myocardial
metabolism and predispose to the diabetic cardiomyopathy. Several
metabolic alterations occur in the pre-diabetic and in the diabetic
state that may heighten the effect of myocardial ischemia and
contribute to the development of diabetic cardiomyopathy.
In diabetics and in subjects with insulin resistance the abnormal-
ities in glucose uptake and utilization are coupled with an increase in
free fatty acid oxidation not only in the skeletal myocytes but also in
the cardiomyocytes. These metabolic changes of the diabetic heart
and skeletal myocytes lead to a diminished production of high
energy phosphate since the beta-oxidation of free fatty acid is less
efﬁcient than the glycolysis in generating energy.
In diabetic and pre-diabetic states a reduced glucose uptake and
utilization coupled with a preferential FFA oxidation occur as
consequence of inadequate insulin receptor signalling or decreased
insulin levels. An important metabolic alteration of diabetes is the
increase free fatty acid concentrations and increased muscular and
myocardial free fatty acid uptake and oxidation. The increased
uptake and utilization of free fatty acid during increased metabolic
demands or during ischemia is responsible for greater decrease of
myocardial performance for given amount of ischemia compared to
non diabetic hearts and for the increased susceptibility of diabetic
heart to myocardial ischemia.
Therefore, the abnormal increase in free fatty acid uptake and
utilization contributes to both the development of contractile
dysfunction and to increased sensitivity of the heart to injury during
ischemia. Furthermore, the decreased energy production of the
diabetic heart related to the decreased glucose utilization and
preferential free fatty acid oxidation leads to important alterations
in calcium homeostasis that are responsible for the impaired systolic
and diastolic function of the diabetic heart.
In diabetic patients with coronary artery disease a therapeutic
approach aimed at an improvement of cardiac metabolism through
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manipulations of the utilization of metabolic substrates should result
in an improvement of myocardial ischemia and of left ventricular
function.
Therefore, the metabolic changes of diabetes alter myocardial
metabolism reducing cardiac susceptibility to ischemic stimuli and
cardiac performance. In diabetic coronary patients the episodes of
transient myocardial ischemia coupled with the chronic myocardial
hypoperfusion cause a progressive decline of left ventricular
function. The inhibition of FFA oxidation improves cardiac metabo-
lism at rest, increases the cardiac ischemic and therefore reduces the
decline of left ventricular function due to chronic hypoperfusion and
repetitive episodes of myocardial ischemia.
doi:10.1016/j.ijcme.2015.05.003
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Bergamot (Citrus Bergamia) is an endemic plant of Calabrian region
in Southern Italy. To date, 95% ofworldwide bergamot production occurs
in the Ionic area of Calabria, where soil characteristics and pH (b6.5–7.5)
are particularly suitable for its cultivation.
Bergamot essential oil (BEO) is made up of a volatile fraction and a
non-volatile residue. Volatile components make up approximately 93–
96% byweight of bergamot oil, while the non-volatile residue represents
the remaining 4–7%. The non-volatile fraction is a mixture of monoter-
pene and sesquiterpene hydrocarbons (such as limonene, γ-terpinene,
and β-pinene) and their oxygenated derivatives (linalool and linalyl
acetate). The non-volatile (4–7% of total) fraction containing coumarins
and psoralens [such as bergapten (5-methoxypsoralen) and berga-
mottine (5-geranyloxypsoralen)]. The non-volatile residue, which
inﬂuences the olfactory properties of the oil, contains waxes and
polymethoxylated ﬂavones other than about 0.2% bergapten which is
responsible for the phototoxicity of BEO. The bergapten-free extract of
the essence (BEO-BF) together with a natural essence deprived of the
hydrocarbon fraction and of bergapten (BEO-HF/BF) are prepared by
extractive industries for perfumery and cosmetic uses [2,3].
Bergamot differs from other citrus fruits not only because of the
composition of these ﬂavonoids, but also because of their particularly
high content. Some of the ﬂavonoids such as naringin, present also in
grapefruit, have already been shown to be active in animal models of
atherosclerosis, while neoeriocitrin and rutin exhibited the strongest
capacity to inhibit LDL oxidation. Importantly, bergamot juice is rich in 3-
hydroxy-3-methylglutaryl neohesperidosides of hesperetin (bru-
tieridine) and naringenin (melitidine) with ability to inhibit HMG-CoA
reductase. These compounds most likely contribute to the important
hypolipemic effects of bergamot juice and vasoprotective effects of
bergamot oil derivatives in rats and in humans as demonstrated by
recent clinical studies carried out in patients treated with bergamot-
derived polyphenolic fraction (BPF) obtained concentrating bergamot
juice in a form of powder, enriched in ﬂavonoids.
Epidemiologic studies have demonstrated that a Mediterranean diet
rich in olive oil is associated with decrease in risk for cardiovascular
disease, obesity, and diabetes. Although some of the protection may be
from the unsaturated fatty acid components of such a diet, additional
smallmolecules found in olive oil and olive plantsmay confer protection,
including the polyphenol oleuropein and hydroxytyrosol.
The two main sources of olive polyphenols are olive leaves and
the waste from the olive oil industry. Olive leaves have the highest
antioxidant and scavenging power among the different parts of the
olive tree. There are ﬁve groups of phenolic compounds principally
present in olive leaves: oleuropeosides (oleuropein and ver-
bascoside); ﬂavones (luteolin-7-glucoside, apigenin-7-glucoside,
diosmetin-7- glucoside, luteolin, and diosmetin); ﬂavonols (rutin);
ﬂavan-3-ols (catechin), and substituted phenols (tyrosol, hydroxy-
tyrosol, vanillin, vanillic acid, and caffeic acid). The most abundant
compound in olive leaves is oleuropein, followed by hydroxytyrosol,
a precursor of oleuropein, the ﬂavone-7-glucosides of luteolin and
apigenin, and verbascoside, a conjugated glucoside of hydroxytyrosol
and caffeic acid.
Oleuropein prevents cardiac disease by protecting membrane
from lipid oxidation, by affecting coronary blood vessel dilation, by
exerting antiarhythmic action, by improving lipid metabolism, by
protecting enzymes, by preventing hypertensive cell death in cancer
patients and by its antiviral properties.
In the current review, we want to highlight the potential
beneﬁcial effects of synergistic action of BPF and oleuropein.
There is evidence to suggest that the anti-hypertensive activity of
the olive leaf extract lies probably in its content of oleuropein acting
synergistically with other active substances to exert both ACE
inhibitory and calcium channel blocking activities.
The anti-hypertensive and cholesterol-lowering actions hypoth-
esized for oleuropein suggest its potential synergistically action with
BPF, able to induce in patients both hypolipemic and hypoglycaemic
effects other than an improvement of reactive vasodilatation. This
latter action also underlines an improvement of endothelial function
in patients at risk of atherosclerosis.
Since oxidative stress has been shown to reduce reactive NO-
dependent vasodilatation, it is likely that BPF may well attenuate
overproduction of oxygen reactive species in the vascular wall
thereby restoring the imbalanced endothelial function in hyperlipe-
mic patients.
doi:10.1016/j.ijcme.2015.05.004
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Background: Overproduction of oxidized-low density lipoproteins
(oxyLDL) has been found to contribute in endothelial cell (EC)
dysfunction thereby leading to atherosclerosis development and
progression. In particular, oxyLDL lead to apoptotic cell death of EC via
oxidative stress production, mostly subsequent to overexpression of the
scavenger receptor LOX-1. Here, we hypothesize that LOX-1 expression
in EC represents a crucial event which attenuates protective autophagic
response, thereby enhancing programmed endothelial cell death.
Methods and results: Bovine aortic endothelial cells (BAEC) in culture
were exposed to oxyLDL (1–100 μM). After 48 h incubation, oxyLDL
produced apoptotic cell death of BAEC as detected by FACS analysis, an
effect counteracted by antioxidant N-acetyl-cysteine (NAC) as well as by
the NO-donor SNAP. OxyLDL-induced apoptotic cell death was also
accompanied by reduced VEGF-dependent phosphorylation of constitu-
tive NO synthase (cNOS) in BAEC and consistent attenuation of
autophagic response as detected by expression of beclin-1 and LC3,
two reliable biomarkers of autophagy. Moreover, silencing LOX-1
receptor signiﬁcantly restored LC3 expression in oxyLDL-treated BAEC,
thus suggesting a key role of LOX-1 overproduction in oxyLDL-induced
endothelial dysfunction.
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